Tech Company Inital Public Offerings
4D Molecular Therapeutics IPO
Based in Emeryville, 4D Molecular Therapeutics is now a public company.
Transaction Overview
Company Name
Announced On
12/10/2020
Transaction Type
IPO
Amount
$193,200,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:$65.0 million to $70.0 million to fund our ongoing and planned clinical and preclinical development of our product candidates, including ongoing clinical trials for 4D-310 and 4D-125 and IND-enabling study activities for 4D-150 and 4D-710;$30.0 million to $35.0 million to fund the further development and expansion of our pipeline including to complete lead optimization and IND-enabling studies for 4D-135, and potentially other research candidates;$5.0 million to $10.0 million to fund the continued expansion of our manufacturing capabilities and facilities; andany remaining amounts for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 455
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Email Address
Overview
4D Molecular Therapeutics (Nasdaq: FDMT) designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/10/2020: HealNow venture capital transaction
Next: 12/10/2020: myInterview venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs